DeutschNewstral
Article
Ppacbiztimes.com on 2019-08-16 17:30
Amgen fends off biosimilar for arthritis drug Enbrel
Related news
- PAmgen gets approval for arthritis drug biosimilarpacbiztimes.com
- PGenentech sues Amgen over biosimilar drug infopacbiztimes.com
- PAmgen seeks license for biosimilar version of oncology drug Rituxanpacbiztimes.com
- PAmgen tackles rheumatoid arthritis with third biosimilar to get FDA OKpacbiztimes.com
- PAmgen’s Humira biosimilar delayed, Enbrel approvedpacbiztimes.com
- PAmgen settles with AbbVie over Humira biosimilarpacbiztimes.com
Colorado moves to cap price of arthritis drug Enbrelpressherald.com- PAmgen asks FDA to approve biosimilar drugpacbiztimes.com
Enbrel Biosimilar in Europe and USjdsupra.com- PFDA approves biosimilar competitor to Amgen’s Enbrelpacbiztimes.com
FDA Approves Novartis’s Biosimilar to Amgen’s Enbrelwsj.com- PFDA approves biosimilar of Amgen’s Enbrelpacbiztimes.com
- PAmgen pilots new drug strategypacbiztimes.com
- PAmgen seeks European OK of biosimilar drug, partners with Merck on studiespacbiztimes.com
- Amgen Sues Pfizer Over Proposed Neulasta Biosimilarjdsupra.com
- PStudy finds Amgen asthma drug is effectivepacbiztimes.com
Novartis wins US OK for biosimilar version of Amgen’s EnbrelDenver Post- PFDA gives full approval to Amgen leukemia drug Blincytopacbiztimes.com
- PFDA approves Amgen biosimilar of AbbVie’s Humirapacbiztimes.com
- PFDA approves Amgen cancer treatment biosimilar Mvasipacbiztimes.com